Inrig Jula, Chief Medical Officer at Travere Therapeutics ($TVTX), sold about $1.02 million in company shares across seven open market transactions over the past year. Her most recent sale occurred on February 4, 2026. These sales rank her 4,861st among 11,678 insiders in our database by total value sold, below the average of $8.6 million per insider and 6.4 transactions. Jula made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 4, 2026 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 1547 | $32.11 | 105,938.0000 | 89,211,813 | 1.44% | 0.00% |
| Feb. 4, 2026 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 232 | $32.85 | 105,706.0000 | 89,211,813 | 0.22% | 0.00% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | A | Employee stock option (right to buy) | 75000 | $0.00 | 75,000.0000 | 89,211,813 | 9999.99% | 0.08% |
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 6956 | $32.12 | 107,485.0000 | 89,211,813 | 6.08% | 0.01% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | A | Common Stock | 28130 | $0.00 | 114,441.0000 | 89,211,813 | 32.59% | 0.03% |
| Jan. 5, 2026 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 2031 | $40.18 | 86,756.0000 | 89,211,813 | 2.29% | 0.00% |
| Jan. 6, 2026 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 445 | $37.75 | 86,311.0000 | 89,211,813 | 0.51% | 0.00% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 15000 | $42.00 | 88,787.0000 | 102,618,560 | 14.45% | 0.01% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | M | Employee stock option (right to buy) | 15000 | $0.00 | 76,000.0000 | 102,618,560 | 16.48% | 0.01% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | M | Common Stock | 15000 | $8.93 | 103,787.0000 | 102,618,560 | 16.89% | 0.01% |
| July 1, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 815 | $14.65 | 88,787.0000 | 78,888,861 | 0.91% | 0.00% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | M | Performance-based restricted stock units | 8000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.01% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | M | Common Stock | 8000 | $0.00 | 92,170.0000 | 78,888,861 | 9.50% | 0.01% |
| Feb. 12, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 2568 | $23.53 | 89,602.0000 | 78,888,861 | 2.79% | 0.00% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | A | Employee stock option (right to buy) | 100000 | $0.00 | 100,000.0000 | 78,888,861 | 9999.99% | 0.13% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | A | Common Stock | 30000 | $0.00 | 89,443.0000 | 78,888,861 | 50.47% | 0.04% |
| Feb. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 4207 | $20.12 | 85,236.0000 | 78,888,861 | 4.70% | 0.01% |
| Feb. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 1066 | $20.11 | 84,170.0000 | 78,888,861 | 1.25% | 0.00% |
| Jan. 6, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 440 | $18.76 | 59,443.0000 | 78,888,861 | 0.73% | 0.00% |
| Jan. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 2066 | $19.10 | 59,883.0000 | 78,888,861 | 3.34% | 0.00% |
| Sept. 10, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 684 | $12.98 | 61,949.0000 | 74,267,418 | 1.09% | 0.00% |
| Sept. 9, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 2191 | $11.52 | 62,633.0000 | 74,267,418 | 3.38% | 0.00% |
| Sept. 5, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | A | Common Stock | 6750 | $0.00 | 64,824.0000 | 74,267,418 | 11.62% | 0.01% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | A | Employee stock option (right to buy) | 91000 | $0.00 | 91,000.0000 | 74,267,418 | 9999.99% | 0.12% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | S | Common Stock | 2174 | $8.53 | 58,074.0000 | 74,267,418 | 3.61% | 0.00% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | CHIEF MEDICAL OFFICER | A | Common Stock | 25000 | $0.00 | 60,248.0000 | 74,267,418 | 70.93% | 0.03% |
| Jan. 3, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | Chief Medical Officer | S | Common Stock | 2069 | $9.48 | 35,688.0000 | 74,267,418 | 5.48% | 0.00% |
| Jan. 4, 2024 | Travere Therapeutics, Inc. | $TVTX | Inrig Jula | Chief Medical Officer | S | Common Stock | 440 | $9.17 | 35,248.0000 | 74,267,418 | 1.23% | 0.00% |